monastyrskyi lab
monastyrskyi lab
andrii.monastyrskyi@moffitt.org
Dr. Monastyrskyi joined the faculty at Moffitt Cancer Center & Research Insitute in April 2019 as an Assistant Member in the Department of Drug Discovery and Molecular Medicine (MM) Program.
He received his Ph.D. in chemistry from the University of South Florida, where he worked with Prof. Roman Manetsch on the synthesis of antimalarial agents based on a 3-aryl-4(1H)-quinolone core structure.
His postdoctoral studies (NIH F32 NRSA Fellow) in synthetic methodology development and drug discovery were carried out at The Scripps Research Institute under the direction of Prof. William R. Roush.
His lab at Moffitt focuses on medicinal chemistry, synthetic organic chemistry, and chemical biology.
Alisa received her Ph.D. in Organic Chemistry from the State Scientific Institution "Institute for Single Crystals" of National Academy of Sciences of Ukraine (2019), where she worked with Prof. Valentyn A. Chebanov on studying properties of 3(5)-aminoisoxazoles in reactions with carbonyl compounds. At Moffitt, her research is focused on developing new selective ULK1 kinase inhibitors to affect tumors cells' autophagy.
Thiyagu.Pandurangan@moffitt.org
Thiyagu has 14+ years of industrial experience in one of the leading Contract Research Organization (CRO) in India, Syngene International Ltd. His current research is focusing on developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers. Specifically, Thiyagu is responsible for design, scale up and synthetic optimization of the gram quantities of lead CDK12/13 inhibitors required for in vivo studies.
Sean joined the group in 2020 and working on development of selective ULK1 modulators for the treatment of RAS-driven cancers
Nada is a rotational student and working on development of selective CDK11 inhibitors for the treatment of breast cancer. She is a second-year student in the Cancer Chemical Biology program at Moffitt Cancer Center. She graduated from Zewail University for Science and Technology, majoring in Biomedical Sciences with special focus on Drug Design and Development along with a minor in Nano-sciences. She worked in the Tumor Biology Research unit at 57357 Children’s Cancer Hospital Egypt (CCHE). She was then appointed as a research and teaching assistant at Zewail City. She is also pursuing her master’s degree in Chemical Biology at Zewail City
Anna is a 3rd year student at the University of South Florida pursuing her B.S. in Biomedical Sciences. At Moffitt, her research is focused on assisting with development of new CDK12 and ULK1 kinase inhibitors. Additionally, Anna is responsible for in vitro ADME assays in the lab (aqueous solubility, logD, microsomal stability etc).
